The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 409-420

  Moley, Jeffrey F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hirschprung's disease; Medullary thyroid cancer; Oncogene; Pheochromocytoma; Thyroidectomy

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; CLINICAL FEATURE; DISEASE CARRIER; DISEASE COURSE; FAMILIAL CANCER; FEMALE; GENE MAPPING; GENE MUTATION; HIRSCHSPRUNG DISEASE; HUMAN; MALE; MISSENSE MUTATION; MOLECULAR GENETICS; NEUROFIBROMATOSIS; ONCOGENE; ONCOGENE RET; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SCREENING; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; DNA MUTATIONAL ANALYSIS; DROSOPHILA PROTEINS; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; MOLECULAR BIOLOGY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0031046849     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.409     Document Type: Review

References (28)

1. Cance W, Wells SJ. 1985. Multiple endocrine neoplasia type 2a. Curr. Prob. Surg. 21:1
2. Moley JF. 1995. Medullary thyroid cancer. Surg. Clin. North Am. 75:405-20
3. Van Heerden J, Grant C, Gharib H, et al. 1990. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 212:395-401
4. O'Riordain DS, O'Brien T, Weaver AL, et al. 1994. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017-23
5. Wells S, Baylin S, Linehan W, et al. 1978. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann. Surg. 188:139-41
6. Mathew C, Chin K, Easton D. 1987. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-28
7. Simpson N, Kidd K, Goodfellow P. 1987. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by genetic linkage. Nature 328:528-30
8. Lairmore TC, Howe JR, Korte JA, et al. 1991. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 9:181-92
9. Mulligan L, Kwok J, Healy C. 1993. Germline mutations of the RET protooncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 363:458-60
10. Donis-Keller H, Dou S, Chi D, et al. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2:851-56
11. Hofstra RM, Landsvater RM, Ceccherini I, et al. 1994. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma [see comments]. Nature 367:375-76
12. Carlson K, Dou S, Chi D, et al. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91:1579-83
13. Takahashi M, Ritz J, Cooper GM. 1985. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42:581-88
14. Grieco M, Santoro M, Berlingleri M, et al. 1990. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-63
15. Santoro M, Rosati R, Grieco M, et al. 1990. The RET proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5:1595-98
16. Edery P, Lyonnet S, Mulligan LM, et al. 1994. Mutations of the RET proto-oncogene in Hirschprung's disease. Nature 367: 378-80
17. Eng C, Smith DP, Mulligan LM, et al. 1995. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10: 509-13
18. Bolino A, Schuffenecker I, Luo Y, et al. 1995. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-19
19. Mulligan LM, Eng C, Healey CS, et al. 1994. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6: 70-74
20. Eng C, Smith DP, Mulligan LM, et al. 1994. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3:237-41 [Erratum. 1994. 3:686]
21. Carlson KM, Bracamontes J, Jackson CE, et al. 1994. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am. J. Hum. Genet. 55:1076-82
22. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, et al. 1995. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J. Clin. Endocrinol. Metab. 80:2063-68
23. Moley J, Brother M, Fong C, et al. 1992. Consistent association of Ip loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res. 52: 770-74
24. Howe J, Lairmore T, Dou S, et al. 1992. Presymptomatic identification of carriers of the MEN 2A gene using flanking DNA markers. Surgery 112:219-26
25. Howe JR, Lairmore TC, Mishra S, et al. 1992. Improved predictive test for MEN2, using flanking dinucleotide repeats and RFLPs. Am. J. Hum. Genet. 51:1430-42
26. Wells SJ, Chi D, Toshima K, et al. 1994. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 220:237-47
27. Borst MJ, VanCamp JM, Peacock ML, Decker RA. 1995. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 117:386-91
28. Lips C, Landsvater R, Hoppener J, et al. 1994. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med. 331:828-35